GSK Files for Albiglutideās Approval
The European Medicines Agency (EMA) recently received a marketing authorization application (MAA) by pharmaceutical giant GlaxoSmithKline (GSK). As per the report, the aim of the company is to bring its albiglutide treatment into picture.
The treatment has been manufactured for adult patients of type-2 diabetes. It is a treatment to be taken once in a week, which is still seeking its approval. The drug currently is endorsed nowhere in the whole world.
It has been found in studies that albiglutide degrades GLP-1 on a fast pace. GLP-1 is a peptide, the report found in the meanwhile, which is secreted normally during a meal from the gastrointestinal tract. The same then helps in release of insulin, thereby controlling rise in the blood sugar after ingestion.
The report said type-2 diabetes patients either have reduced levels of GLP-1 or they simply do not have it.
The biggest drug-maker in Britain also filed for regulatory approval of the drug in the US, as the firm reported on Thursday. It was in an attempt to hold a strong position in a crowded market and it realized an increase in its share price on the day as well. The same was up by 0.48% at 1,480p for the company by 13:15.